JP2025501755A - 脆弱ｘ関連障害に対する治療的処置 - Google Patents

脆弱ｘ関連障害に対する治療的処置 Download PDF

Info

Publication number
JP2025501755A
JP2025501755A JP2024538030A JP2024538030A JP2025501755A JP 2025501755 A JP2025501755 A JP 2025501755A JP 2024538030 A JP2024538030 A JP 2024538030A JP 2024538030 A JP2024538030 A JP 2024538030A JP 2025501755 A JP2025501755 A JP 2025501755A
Authority
JP
Japan
Prior art keywords
fmr1
aso
rna
fxs
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501755A5 (https=
Inventor
ディー リヒター ジョエル
シャー スネーハ
ワッツ ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of JP2025501755A publication Critical patent/JP2025501755A/ja
Publication of JP2025501755A5 publication Critical patent/JP2025501755A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024538030A 2021-12-23 2022-12-23 脆弱ｘ関連障害に対する治療的処置 Pending JP2025501755A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265989P 2021-12-23 2021-12-23
US63/265,989 2021-12-23
PCT/US2022/082380 WO2023122800A1 (en) 2021-12-23 2022-12-23 Therapeutic treatment for fragile x-associated disorder

Publications (2)

Publication Number Publication Date
JP2025501755A true JP2025501755A (ja) 2025-01-23
JP2025501755A5 JP2025501755A5 (https=) 2026-01-06

Family

ID=85199427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538030A Pending JP2025501755A (ja) 2021-12-23 2022-12-23 脆弱ｘ関連障害に対する治療的処置

Country Status (9)

Country Link
EP (1) EP4453212A1 (https=)
JP (1) JP2025501755A (https=)
KR (1) KR20240133725A (https=)
CN (1) CN118679257A (https=)
AU (1) AU2022417615A1 (https=)
CA (1) CA3240593A1 (https=)
IL (1) IL313726A (https=)
MX (1) MX2024007908A (https=)
WO (1) WO2023122800A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240947A1 (en) * 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
WO1998010090A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
EP2595663A4 (en) * 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
EP2723902A4 (en) * 2011-06-24 2015-02-18 Murdoch Childrens Res Inst TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND DISEASES
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
CA2921457A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Heterochromatin forming non-coding rnas
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
GB2574243A (en) * 2018-05-31 2019-12-04 The Govening Council Of The Univ Of Toronto Adeno-associated viral vector-mediated gene therapy for treating fragile X-associated disorders
CA3130854A1 (en) * 2019-02-26 2020-09-03 Nogra Pharma Limited Fragile x mental retardation protein interfering oligonucleotides and methods of using same
CN120022385A (zh) * 2019-05-07 2025-05-23 洛桑联邦理工学院 Fmrp及癌症治疗
CN113151406B (zh) * 2021-03-25 2022-06-21 深圳会众生物技术有限公司 Fmr1基因cgg重复数及甲基化检测试剂盒和检测方法

Also Published As

Publication number Publication date
MX2024007908A (es) 2024-09-10
EP4453212A1 (en) 2024-10-30
WO2023122800A1 (en) 2023-06-29
CN118679257A (zh) 2024-09-20
KR20240133725A (ko) 2024-09-04
CA3240593A1 (en) 2023-06-29
IL313726A (en) 2024-08-01
AU2022417615A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
US20180312839A1 (en) Methods and compositions for increasing smn expression
EP3394259B1 (en) Compositions and methods for decreasing tau expression
CA3099522C (en) GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY
AU2015207351C1 (en) Materials and methods for modulation of tendon healing
JP2025526712A (ja) オリゴヌクレオチド組成物及びその方法
JP2016534035A (ja) 筋萎縮性側索硬化症を治療するための組成物及び方法
JP2023538284A (ja) Ｐｌｐ１発現を阻害するための組成物及び方法
Schnöder et al. Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or tau-transgenic Alzheimer's mouse models
CN107847553A (zh) 治疗具有tp53的半合子缺失的癌症的方法
WO2020257631A2 (en) Ppm1a inhibitors and methods of using same
JP2024020338A (ja) 白斑を処置するための方法及び組成物
Khodabakhsh et al. MicroRNA‐140‐5p inhibitor attenuates memory impairment induced by amyloid‐ß oligomer in vivo possibly through Pin1 regulation
JP2025501755A (ja) 脆弱ｘ関連障害に対する治療的処置
KR20250155076A (ko) 안티센스 올리고머 제형
US20240417729A1 (en) Therapeutic treatment for fragile x-associated disorder
US9993522B2 (en) Treatment of pain by inhibition of USP5 de-ubiquitinase
JP2024509845A (ja) 癌を診断し、治療する方法におけるプロトカドヘリンの使用
HK40111268A (zh) 用於脆性x相关病症的治疗性治疗
WO2025240947A1 (en) Therapeutic treatment for fragile x-associated disorder
EP4215614A1 (en) Combination therapy for dystrophin-related diseases
US20190055553A1 (en) Methods for identifying and targeting non-coding rna scaffolds
JP2026504808A (ja) 神経変性疾患の処置のためのポリヌクレオチド組成物および方法
Lin The Role of Small Nucleolar Rnas in Major Depressive Disorder and Antidepressant Treatment
Vizinha Targeting miR-124 in motor neurons as a therapeutic strategy to prevent neurodegeneration and glial activations in ALS
Assi et al. Inhibition of Histone Demethylases as an Approach to Restore Deficient H3K79 Methylation in Osteoarthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251222